Drugs / AD-230
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07521241 | May → Jun 2026 overdue | liver disorder | Addpharma Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07618845 | May → Jul 2026 overdue | liver disorder | Addpharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07521241 ↗ |
| Route | Oral | “Oral administration of AD-230 or AD-2301, according to randomized sequence.” NCT07521241 ↗ |